Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

The approval adds a new indication for GLP-1 drugs and gives Novo an advantage over Lilly’s rival diabetes drug Mounjaro, ...

The number of prescriptions for obesity medications rose an average of 5.3% annually from 2017 to 2024 and corresponded with ...

The U.S. Food and Drug Administration (FDA) has approved pharmaceutical company Novo Nordisk’s (NVO) Ozempic medication to ...

Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus.

The widespread acceptance of the so-called GLP-1 drugs, Zepbound by Eli Lilly and Wegovy by Novo Nordisk, for weight loss has created a game-changing dynamic for the overall health of the 72% of ...